(-0.26%) 5 022.49 points
(0.04%) 37 832 points
(-0.11%) 15 641 points
(-0.90%) $81.19
(-2.91%) $1.933
(0.34%) $2 310.80
(0.49%) $26.79
(1.69%) $964.20
(-0.11%) $0.936
(-0.15%) $11.08
(0.06%) $0.801
(-0.12%) $93.33
-0.22% $ 42.24
Live Chart Being Loaded With Signals
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories...
Stats | |
---|---|
Volumen de hoy | 49 031.00 |
Volumen promedio | 1.07M |
Capitalización de mercado | 9.35B |
EPS | $0.550 ( 2024-04-29 ) |
Próxima fecha de ganancias | ( $0.440 ) 2024-06-21 |
Last Dividend | $1.087 ( 2017-01-25 ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.61 |
ATR14 | $0.0570 (0.13%) |
Volumen Correlación
Qiagen NV Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Qiagen NV Correlación - Moneda/Commodity
Qiagen NV Finanzas
Annual | 2023 |
Ingresos: | $1.97B |
Beneficio Bruto: | $1.22B (62.23 %) |
EPS: | $1.540 |
FY | 2023 |
Ingresos: | $1.97B |
Beneficio Bruto: | $1.22B (62.23 %) |
EPS: | $1.540 |
FY | 2022 |
Ingresos: | $2.14B |
Beneficio Bruto: | $1.38B (64.65 %) |
EPS: | $1.920 |
FY | 2021 |
Ingresos: | $2.25B |
Beneficio Bruto: | $1.45B (64.43 %) |
EPS: | $2.25 |
Financial Reports:
No articles found.
Qiagen NV Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00208 | 2002-12-26 |
Last Dividend | $1.087 | 2017-01-25 |
Next Dividend | $0 | N/A |
Payout Date | 2017-01-31 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $1.089 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.39 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.37 | |
Div. Directional Score | 7.23 | -- |
Year | Amount | Yield |
---|---|---|
2002 | $0.00208 | 0.01% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $1.087 | 3.71% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.174 | 1.500 | 6.53 | 9.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.0558 | 1.200 | 8.14 | 9.77 | [0 - 0.3] |
returnOnEquityTTM | 0.0930 | 1.500 | -0.0782 | -0.117 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.990 | 0.800 | 5.05 | 4.04 | [1 - 3] |
quickRatioTTM | 1.458 | 0.800 | 6.13 | 4.90 | [0.8 - 2.5] |
cashRatioTTM | 0.619 | 1.500 | 7.67 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.251 | -1.500 | 5.82 | -8.74 | [0 - 0.6] |
interestCoverageTTM | 8.73 | 1.000 | 7.88 | 7.88 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.33 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.402 | -1.500 | 8.39 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.643 | 1.000 | 2.62 | 2.62 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.237 | 1.000 | 7.26 | 7.26 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.300 | 1.000 | 9.45 | 9.45 | [0.2 - 2] |
assetTurnoverTTM | 0.321 | 0.800 | -1.191 | -0.953 | [0.5 - 2] |
Total Score | 10.09 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 27.46 | 1.000 | 7.33 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0930 | 2.50 | -0.0503 | -0.117 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.55 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.488 | 1.500 | -0.0789 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.66 | 0 | [0.1 - 0.5] |
Total Score | 4.37 |
Qiagen NV
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico